UY25590A1 - Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos - Google Patents
Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicosInfo
- Publication number
- UY25590A1 UY25590A1 UY25590A UY25590A UY25590A1 UY 25590 A1 UY25590 A1 UY 25590A1 UY 25590 A UY25590 A UY 25590A UY 25590 A UY25590 A UY 25590A UY 25590 A1 UY25590 A1 UY 25590A1
- Authority
- UY
- Uruguay
- Prior art keywords
- formula
- pain
- inflammatory
- procedure
- indole compounds
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000000730 antalgic agent Substances 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 3
- 230000036407 pain Effects 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 206010037660 Pyrexia Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 150000002475 indoles Chemical class 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 102100027456 Cytochrome c oxidase subunit 2 Human genes 0.000 abstract 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 abstract 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029155 Nephropathy toxic Diseases 0.000 abstract 1
- -1 R1 is H Chemical group 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- AKBZGRBYTSHPNP-UHFFFAOYSA-N ethyl 2-(2-benzoyl-6-chloro-1h-indol-3-yl)acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OCC)=C1C(=O)C1=CC=CC=C1 AKBZGRBYTSHPNP-UHFFFAOYSA-N 0.000 abstract 1
- 230000027950 fever generation Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000007694 nephrotoxicity Effects 0.000 abstract 1
- 231100000417 nephrotoxicity Toxicity 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Procedimiento para preparar derivados de indol (FÓRMULA I)como agentes farmaceuticos para el tratamiento o alivio del dolor y la inflamación y de otros transtornos asociados con la inflamación, tales como la artritis. Los compuestos de indol de esta invención tienen inhibición de la COX, preferiblemente COX2, por lo que tambien tiene actividad donde este implocada las prostaglandinas como patógenos, aliviando dolor, fiebre, etc. Tambien estan asociados al tratamiento del cáncer de colon,mama, piel, etc. También incluye osteoartritis, pirexia, asma, reabsorción osea, nefrotoxicidad, dolor, cáncer, Alzheimer. Los compuestos de fórmula I, donde z es OH, alcoxi, -NR2R3 o un grupo de fórmula II o III, donde r es 1,2,3,4; Y es un enlace directo, O, S o NR4 y W e OH o NR2R3,Q es fenilo, un grupo aromáticomonocíclico de 5 eslabones o de 6 eslabones, cicloalquilo C3-7, un heterociclo condensado, R1 es H, alquilo o halo, X es halo, alquilo, OH, etc Ejemplo: (2-benzoil-6-cloro-1H-indol-3-il)acetato de etilo
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9800003 | 1998-01-05 | ||
| UY25332A UY25332A1 (es) | 1998-01-05 | 1998-12-31 | Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25590A1 true UY25590A1 (es) | 1999-09-27 |
Family
ID=11004645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25332A UY25332A1 (es) | 1998-01-05 | 1998-12-31 | Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos |
| UY25590A UY25590A1 (es) | 1998-01-05 | 1999-06-28 | Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25332A UY25332A1 (es) | 1998-01-05 | 1998-12-31 | Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US6608070B1 (es) |
| EP (1) | EP1045833B1 (es) |
| JP (1) | JP3347136B2 (es) |
| KR (1) | KR100404054B1 (es) |
| CN (1) | CN1284064A (es) |
| AP (1) | AP869A (es) |
| AR (1) | AR016977A1 (es) |
| AT (1) | ATE308519T1 (es) |
| AU (1) | AU748107B2 (es) |
| BG (1) | BG104643A (es) |
| BR (1) | BR9813124A (es) |
| CA (1) | CA2316863A1 (es) |
| CO (1) | CO4970807A1 (es) |
| DE (1) | DE69832200T2 (es) |
| DZ (1) | DZ2700A1 (es) |
| EA (1) | EA200000614A1 (es) |
| ES (1) | ES2255190T3 (es) |
| GT (1) | GT199800205A (es) |
| HN (1) | HN1997000098A (es) |
| HR (1) | HRP20000454A2 (es) |
| HU (1) | HUP0102922A3 (es) |
| ID (1) | ID24876A (es) |
| IL (1) | IL136885A0 (es) |
| IS (1) | IS5532A (es) |
| MA (1) | MA24736A1 (es) |
| NO (1) | NO20003451L (es) |
| OA (1) | OA11441A (es) |
| PA (1) | PA8466201A1 (es) |
| PE (1) | PE20000055A1 (es) |
| PL (1) | PL341696A1 (es) |
| SA (1) | SA99191299A (es) |
| SK (1) | SK9912000A3 (es) |
| TN (1) | TNSN99001A1 (es) |
| TR (1) | TR200001906T2 (es) |
| TW (1) | TW436482B (es) |
| UY (2) | UY25332A1 (es) |
| WO (1) | WO1999035130A1 (es) |
| YU (1) | YU41600A (es) |
| ZA (1) | ZA9911B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555540B1 (en) * | 1999-06-30 | 2003-04-29 | Pfizer Inc | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| DE60000556T2 (de) * | 1999-07-02 | 2003-02-13 | Pfizer Inc., New York | Tetrazolylalkyl-Indolderivate als entzündungshemmende und analgetische Mittel |
| MXPA00006605A (es) * | 1999-07-02 | 2004-12-09 | Pfizer | Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. |
| PT1175214E (pt) | 1999-12-08 | 2005-04-29 | Pharmacia Corp | Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico |
| AU2003299757A1 (en) * | 2002-12-19 | 2004-07-14 | Elan Pharmaceuticals Inc. | Substituted n-phenyl sulfonamide bradykinin antagonists |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) * | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| PL1534305T3 (pl) | 2003-05-07 | 2007-03-30 | Osteologix As | Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie |
| KR100795462B1 (ko) | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| AU2007311026B2 (en) | 2006-10-17 | 2012-05-17 | Stiefel Laboratories, Inc. | Talarazole metabolites |
| US20120022121A1 (en) * | 2007-11-29 | 2012-01-26 | Dalton James T | Indoles, derivatives and analogs thereof and uses therefor |
| JP2013525355A (ja) * | 2010-04-19 | 2013-06-20 | メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー | チアゾリジンジオン化合物の新規合成 |
| ES2547890T3 (es) | 2010-07-07 | 2015-10-09 | Ardelyx, Inc. | Compuestos y métodos para inhibir el transporte de fosfato |
| WO2012006474A2 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5823514B2 (ja) | 2010-07-07 | 2015-11-25 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| EP2590510B1 (en) | 2010-07-07 | 2016-09-28 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| NZ606574A (en) | 2010-08-10 | 2015-02-27 | Metabolic Solutions Dev Co Llc | Novel synthesis for thiazolidinedione compounds |
| CA2807815C (en) | 2010-08-10 | 2018-10-02 | Metabolic Solutions Development Company, Llc | Novel synthesis for thiazolidinedione compounds |
| WO2013138600A1 (en) * | 2012-03-16 | 2013-09-19 | Rosen Eliot M | Radioprotector compounds |
| US9808443B1 (en) | 2016-11-28 | 2017-11-07 | King Saud University | Cyclooxygenase inhibitors |
| CN111004121A (zh) * | 2019-12-09 | 2020-04-14 | 南京杰运医药科技有限公司 | 一种4-烷氧基乙酰乙酸酯类化合物的制备方法 |
| CN112409281B (zh) * | 2020-08-20 | 2022-11-18 | 上海大学 | (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法 |
| IL305573A (en) | 2021-03-15 | 2023-10-01 | Saul Yedgar | HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES |
| EP4353262A4 (en) * | 2021-06-10 | 2025-05-21 | UIF (University Industry Foundation), Yonsei University | NEW COMPOUND WITH INHIBITORY EFFECT AGAINST PENDRIN AND PHARMACEUTICAL USES THEREOF |
| CN116262721A (zh) * | 2023-01-12 | 2023-06-16 | 浙江师范大学 | 一种二氢吲哚衍生物及吲哚衍生物的制备方法及产品 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5510368A (en) * | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
| CO5190664A1 (es) * | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
-
1998
- 1998-12-17 AP APAP/P/1998/001423A patent/AP869A/en active
- 1998-12-18 EP EP98959082A patent/EP1045833B1/en not_active Expired - Lifetime
- 1998-12-18 TR TR2000/01906T patent/TR200001906T2/xx unknown
- 1998-12-18 DE DE69832200T patent/DE69832200T2/de not_active Expired - Fee Related
- 1998-12-18 US US09/355,494 patent/US6608070B1/en not_active Expired - Fee Related
- 1998-12-18 SK SK991-2000A patent/SK9912000A3/sk unknown
- 1998-12-18 CN CN98813530A patent/CN1284064A/zh active Pending
- 1998-12-18 ID IDW20001286A patent/ID24876A/id unknown
- 1998-12-18 PL PL98341696A patent/PL341696A1/xx unknown
- 1998-12-18 YU YU41600A patent/YU41600A/sh unknown
- 1998-12-18 HU HU0102922A patent/HUP0102922A3/hu unknown
- 1998-12-18 AU AU15005/99A patent/AU748107B2/en not_active Ceased
- 1998-12-18 ES ES98959082T patent/ES2255190T3/es not_active Expired - Lifetime
- 1998-12-18 CA CA002316863A patent/CA2316863A1/en not_active Abandoned
- 1998-12-18 BR BR9813124-9A patent/BR9813124A/pt not_active IP Right Cessation
- 1998-12-18 IL IL13688598A patent/IL136885A0/xx unknown
- 1998-12-18 KR KR10-2000-7007419A patent/KR100404054B1/ko not_active Expired - Fee Related
- 1998-12-18 WO PCT/IB1998/002065 patent/WO1999035130A1/en not_active Ceased
- 1998-12-18 HR HR20000454A patent/HRP20000454A2/hr not_active Application Discontinuation
- 1998-12-18 JP JP2000527531A patent/JP3347136B2/ja not_active Expired - Fee Related
- 1998-12-18 AT AT98959082T patent/ATE308519T1/de not_active IP Right Cessation
- 1998-12-18 EA EA200000614A patent/EA200000614A1/ru unknown
- 1998-12-22 TW TW087120865A patent/TW436482B/zh active
- 1998-12-28 HN HN1997000098A patent/HN1997000098A/es unknown
- 1998-12-28 PE PE1998001288A patent/PE20000055A1/es not_active Application Discontinuation
- 1998-12-29 GT GT199800205A patent/GT199800205A/es unknown
- 1998-12-30 CO CO98077588A patent/CO4970807A1/es unknown
- 1998-12-31 UY UY25332A patent/UY25332A1/es not_active IP Right Cessation
-
1999
- 1999-01-04 MA MA25414A patent/MA24736A1/fr unknown
- 1999-01-04 AR ARP990100010A patent/AR016977A1/es not_active Application Discontinuation
- 1999-01-04 DZ DZ990001A patent/DZ2700A1/xx active
- 1999-01-04 ZA ZA9900011A patent/ZA9911B/xx unknown
- 1999-01-04 TN TNTNSN99001A patent/TNSN99001A1/fr unknown
- 1999-01-05 PA PA19998466201A patent/PA8466201A1/es unknown
- 1999-04-13 SA SA99191299A patent/SA99191299A/ar unknown
- 1999-06-28 UY UY25590A patent/UY25590A1/es not_active Application Discontinuation
-
2000
- 2000-06-13 IS IS5532A patent/IS5532A/is unknown
- 2000-06-30 OA OA1200000195A patent/OA11441A/en unknown
- 2000-07-04 NO NO20003451A patent/NO20003451L/no unknown
- 2000-07-28 BG BG104643A patent/BG104643A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25590A1 (es) | Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos | |
| BR0212611A (pt) | Compostos de pirazolila substituìdos para o tratamento da inflamação | |
| ES2165969T3 (es) | Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios. | |
| BR0015911A (pt) | Derivados de benzoimidazole úteis como agentes antiproliferativos | |
| BR0212613A (pt) | Compostos de indazol substituìdos para o tratamento de inflamação | |
| BR0307796A (pt) | Derivados tricìclicos de pirazol para o tratamento de inflamação | |
| AR024944A1 (es) | Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion | |
| ES2196377T3 (es) | Derivados de naftiridina. | |
| ES2039919T3 (es) | Procedimiento de fabricacion y acondicionamiento de un distribuidor de bolsa, sub-acoplamientos y distribuidores correspondientes. | |
| BR9709959A (pt) | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas | |
| ES2075845T3 (es) | 3,5-di-terc-butil-4-hidroxifenil-1,3,4-tiadiazoles, oxadiazoles y 3,5-di-terc-butil-4-hidroxifenil-1,2,4-tiadiazoles, oxadiazoles y triazoles como agentes antiinflamatorios. | |
| BR0213094A (pt) | Derivados de cromano como ligandos de 5-hidroxi-triptamina-6 | |
| ATE301460T1 (de) | Zubereitung zur prophylaxe oder behandlung der demenz-erkrankung enthaltend ein hydroxyzimtsäurederivat oder einen extrakt einer pflanze der gattung angelica, der diese säure enthält. | |
| PA8532201A1 (es) | Derivados de fenil cetonas sustituidas como antagonistas de ip | |
| ES2068742B1 (es) | Nuevos derivados de piridinio. | |
| ES2184880T3 (es) | Asociacion hormonal estrogeno-progestageno, su procedimiento de preparacion y su utilizacion en medicamentos. | |
| BR9911250A (pt) | Processo para preparação de compostos | |
| PT98773A (pt) | Processo para a preparacao de di-hidropirido/4,3-d/pirimidinas substituidas na posicao 4 e de composicoes farmaceuticas analgesicas e antiinflamatorias que as contem | |
| ES2188908T3 (es) | Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos. | |
| ES2131300T3 (es) | Derivados triciclicos y composiciones farmaceuticas que los contienen. | |
| PA8471801A1 (es) | Derivados de higromicina a | |
| ECSP003590A (es) | Compuestos calcioliticos | |
| ES2191170T3 (es) | Nuevos (-)-enantiomeros de derivados de cis-3,4-cromano utiles en la prevencion y tratamiento de sindromes o enfermedades relacionadas con el estrogeno. | |
| JPS5583758A (en) | Novel 3*44diazaabicyclo*4*1*0*heptenee*2**onee *5**its manufacture and medicine containing it | |
| PA8471901A1 (es) | Derivados de 2"-desoxi higromicina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20110405 |